Showing results (1-10 of 466) with videos related to
Sort By:
Pageof 47
The Oncologist|April 5, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerLecia V SequistJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patientsLecia V SequistJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Update on epidermal growth factor receptor inhibitor development in lung cancerLecia V Sequist, Rafal DziadziuszkoCancer Journal (Sudbury, Mass.)|September 22, 2015
Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment OptionsZofia Piotrowska, Lecia V SequistJAMA Oncology|May 20, 2016
Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A ReviewZofia Piotrowska, Lecia V SequistSeminars in Respiratory and Critical Care Medicine|July 30, 2005
Treatment of advanced non-small cell lung cancer in the elderlyLecia V Sequist, Panos FidiasCurrent Treatment Options in Oncology|August 3, 2010
Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HhJoel W Neal, Lecia V SequistAnnual Review of Medicine|August 25, 2007
EGFR tyrosine kinase inhibitors in lung cancer: an evolving storyLecia V Sequist, Thomas J LynchBiomarkers in Medicine|May 19, 2010
Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitorsNathan A Pennell, Lecia V SequistClinical Advances in Hematology & Oncology : H&O|April 14, 2010
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutationsJoel W Neal, Lecia V SequistPageof 47